Table 1 Baseline patient characteristics stratified according to pre-treatment DTC status
Variable | No. of patients [n = 48] | DTC positive [n = 15] | DTC negative [n = 33] | P value |
|---|---|---|---|---|
Median age (range) | 67 [41–79] | 63 [46–74] | 67 [41–79] | 0.5 |
Sex (%) | 0.5 | |||
Female | 20 (42) | 5 (33) | 15 (45) | |
Male | 28 (58) | 10 (67) | 18 (55) | |
Primary tumor location (%) | 0.8 | |||
Head | 19 (40) | 4 (27) | 15 (45) | |
Body | 7 (15) | 3 (20) | 4 (12) | |
Tail | 7 (15) | 2 (13) | 5 (15) | |
Unknowna | 15 (31) | 6 (40) | 9 (27) | |
Clinical T stage (%) | 0.03 | |||
T1 | 1 (2) | 0 (0) | 1 (3) | |
T2 | 14 (29) | 8 (53) | 6 (18) | |
T3 | 7 (15) | 3 (20) | 4 (12) | |
T4 | 20 (42) | 3 (20) | 17 (52) | |
Txa | 6 (13) | 1 (7) | 5 (15) | |
Clinical N stage (%) | 0.2 | |||
N0 | 19 (40) | 7 (47) | 12 (36) | |
N1 | 16 (33) | 4 (27) | 12 (26) | |
N2 | 3 (6) | 0 (0) | 3 (9) | |
Nx | 10 (21) | 4 (27) | 6 (18) | |
Clinical M stage (%) | 0.5 | |||
M0 | 11 (23) | 2 (13) | 9 (27) | |
M1 | 37 (77) | 13 (87) | 24 (73) | |
Metastasis location (%) | 0.5 | |||
Only liver | 24 (50) | 9 (60) | 15 (45) | |
Only lung | 3 (6) | 2 (13) | 1 (3) | |
Multiple organsb | 3 (6) | 1 (7) | 2 (6) | |
Peritoneal carcinomatosis | 7 (15) | 1 (7) | 6 (18) | |
None | 11 (23) | 2 (13) | 9 (27) | |
ECOG status (%) | 0.5 | |||
0 | 13 (27) | 3 (20) | 10 (30) | |
1 | 29 (60) | 10 (67) | 19 (58) | |
2 | 6 (13) | 2 (13) | 4 (12) | |
First-line treatment (%)c | 0.3 | |||
Gemcitabine | 5 (10) | 4 (27) | 1 (3) | |
Gemcitabine + Abraxane | 24 (50) | 7 (47) | 17 (52) | |
FOLFIRINOX | 19 (40) | 4 (27) | 15 (45) | |
Second-line treatment (%) | 0.4 | |||
Yes | 18 (38) | 4 (27) | 14 (42) | |
No | 30 (62) | 11 (73) | 19 (58) | |
Study site (%) | 0.4 | |||
Stavanger | 42 (88) | 12 (80) | 30 (91) | |
Bergen | 6 (13) | 3 (20) | 3 (9) |